Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Interleukin-2 and regulatory T cells in rheumatic diseases
Antonios G.A. Kolios, George C. Tsokos, David Klatzmann
Nature Reviews Rheumatology (2021) Vol. 17, Iss. 12, pp. 749-766
Closed Access | Times Cited: 82

Showing 1-25 of 82 citing articles:

T cells in health and disease
Lina Sun, Yanhong Su, Anjun Jiao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 277
Targeted Immunotherapy for Autoimmune Disease
Seung Min Jung, Wan‐Uk Kim
Immune Network (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 101
Strategies to therapeutically modulate cytokine action
Warren J. Leonard, Jian‐Xin Lin
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 10, pp. 827-854
Closed Access | Times Cited: 50
Autoimmune diseases and atherosclerotic cardiovascular disease
Florentina Porsch, Christoph J. Binder
Nature Reviews Cardiology (2024) Vol. 21, Iss. 11, pp. 780-807
Closed Access | Times Cited: 14
Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial
Jens Y. Humrich, P. Cacoub, Michèlle Rosenzwajg, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 12, pp. 1685-1694
Closed Access | Times Cited: 63
Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome
Jing He, Jiali Chen, Miao Miao, et al.
JAMA Network Open (2022) Vol. 5, Iss. 11, pp. e2241451-e2241451
Open Access | Times Cited: 42
Therapeutic potential of interleukin-2 in autoimmune diseases
Yeshuang Yuan, Antonios G.A. Kolios, Yudong Liu, et al.
Trends in Molecular Medicine (2022) Vol. 28, Iss. 7, pp. 596-612
Closed Access | Times Cited: 35
New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic review
Renaud Felten, Marc Scherlinger, Philippe Mertz, et al.
Joint Bone Spine (2023) Vol. 90, Iss. 2, pp. 105523-105523
Open Access | Times Cited: 33
Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis
Fan Jiang, Yinping Liu, Yong Xue, et al.
International Immunopharmacology (2023) Vol. 115, pp. 109728-109728
Open Access | Times Cited: 25
IL-2 immunotherapy for targeting regulatory T cells in autoimmunity
Valentina Lykhopiy, Vanshika Malviya, Stéphanie Humblet‐Baron, et al.
Genes and Immunity (2023) Vol. 24, Iss. 5, pp. 248-262
Open Access | Times Cited: 21
Boosting regulatory T cell function for the treatment of autoimmune diseases – That’s only half the battle!
Janine Schlöder, Fatemeh Zare Shahneh, Franz-Joseph Schneider, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 32
Phosphofructokinase P fine-tunes T regulatory cell metabolism, function, and stability in systemic autoimmunity
Marc Scherlinger, Wenliang Pan, Ryo Hisada, et al.
Science Advances (2022) Vol. 8, Iss. 48
Open Access | Times Cited: 28
Total synthesis of interleukin-2 via a tunable backbone modification strategy
Hongxiang Wu, Yi Tan, Wai Lok Ngai, et al.
Chemical Science (2023) Vol. 14, Iss. 6, pp. 1582-1589
Open Access | Times Cited: 16
Steering and controlling evolution — from bioengineering to fighting pathogens
Michael Lässig, Ville Mustonen, Armita Nourmohammad
Nature Reviews Genetics (2023) Vol. 24, Iss. 12, pp. 851-867
Open Access | Times Cited: 15
Giant Cell Arteritis: Advances in Understanding Pathogenesis and Implications for Clinical Practice
Marino Paroli, Rosalba Caccavale, Daniele Accapezzato
Cells (2024) Vol. 13, Iss. 3, pp. 267-267
Open Access | Times Cited: 5
Novel therapeutic strategies targeting abnormal T-cell signaling in systemic lupus erythematosus
Masayuki Mizui, Michihito Kono
Clinical Immunology (2024) Vol. 262, pp. 110182-110182
Closed Access | Times Cited: 4
Exploring the therapeutic potential of regulatory T cell in rheumatoid arthritis: Insights into subsets, markers, and signaling pathways
Q. Y. Su, Huan-Cheng Li, Xiaojing Jiang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116440-116440
Open Access | Times Cited: 4
Induction of regulatory T cells and efficacy of low-dose interleukin-2 in systemic sclerosis: interventional open-label phase 1–phase 2a study
F. Barde, Roberta Lorenzon, Éric Vicaut, et al.
RMD Open (2024) Vol. 10, Iss. 2, pp. e003500-e003500
Open Access | Times Cited: 4
Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis
Xiao Huan, Rui Zhao, Jie Song, et al.
BMC Immunology (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 22
Role of Innate and Adaptive Cytokines in the Survival of COVID-19 Patients
Jorge Monserrat, Ana M. Gómez-Lahoz, Miguel Á. Ortega, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10344-10344
Open Access | Times Cited: 22
Terminalia ferdinandiana Exell. extracts reduce pro-inflammatory cytokine and PGE2 secretion, decrease COX-2 expression and down-regulate cytosolic NF-κB levels
Ian Edwin Cock
Inflammopharmacology (2024) Vol. 32, Iss. 3, pp. 1839-1853
Open Access | Times Cited: 3
Functional Diversities of Regulatory T Cells in the Context of Cancer Immunotherapy
Ran Gao, Guo‐Ping Shi, Jing Wang
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 20
Jak Inhibitors for Treatment of Autoimmune Diseases: Lessons from Systemic Sclerosis and Systemic Lupus Erythematosus
Przemysław Kotyla, Olga Gumkowska-Sroka, Bartosz Wnuk, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 8, pp. 936-936
Open Access | Times Cited: 17
mTOR signaling: A pivotal player in Treg cell dysfunction in systemic lupus erythematosus
Xingyun Zhao, Shifen Wang, Shengjun Wang, et al.
Clinical Immunology (2022) Vol. 245, pp. 109153-109153
Closed Access | Times Cited: 16
Low-dose IL-2 reduces IL-21+ T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes
Jiayuan Zhang, Fiona Hamey, Dominik Trzupek, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top